Dermatology business

Valeant Has Reported a Net Income of $7.64m for The Third Quarter
Nov 28, 2012
Valeant Pharmaceuticals has reported a net income of $7.64m, or $0.02 per diluted share, for the third quarter ended 30 September 2012 compared to $40.86m, or $0.13 per diluted share, for the third quarter ended 30 September 2011. Total ...

Tags: Neurology, organic growth, Dermatology business